Samsung Ventures, a key player in the life sciences sector, has made a strategic investment in BrickBio, Inc., a preclinical-stage biopharmaceutical compan...
– Proceeds will be used to complete clinical demonstration trials of the lead candidate drug RNDP-001 for the treatment of Parkinson's di...
AstraZeneca intends to invest £450 million to research, develop and manufacture vaccines in Speke, Liverpool, a facility which will be operationall...
Immediately after the effective time of the Acquisition, and before giving effect to the concurrent private placement the former stockholders of Bi...
Willow Biosciences, a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ing...
FogPharma®, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently availabl...
Curve Therapeutics, a pioneering biotechnology firm, announced a significant £40.5 million Series A funding round, led by Pfizer Ventures and joined ...
The round also included premier investors such as WI Harper Group, a leading cross-border venture capital firm, and SEEDS Capital, the investment arm of go...
New investment from DRW Venture Capital LLC and Tolmar International Ltd Funds will be used to advance its proprietary, silica-based, drug delivery...
Pfizer does not endorse TRC Capital Investment’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in respons...
QIAGEN announced a strategic plan to step up investments over the next five years in its market-leading QIAGEN Digital Insights (QDI) business. These inve...
Inaugural strategy is one of the largest ever first-time private life sciences growth funds Fundraise closed above its original target, reflecting stron...
This investment opportunity offers a unique chance for individuals and institutions to actively participate in the growth and transformation of the healthc...
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.&nb...
© 2024 Biopharma Boardroom. All Rights Reserved.
